|
Resistance rates in China, U.S. and Kuwait, hospital surveillance data for 2001 |
|||||
| From Tables 1,2,3,8 and 9; Unit: % |
|||||
|
|
|||||
| Bacterium(a) |
Antibiotic(s) |
Pair |
China |
U.S. |
Kuwait |
|
|
|||||
| SAU |
Methicillin |
A |
37 |
38 |
9 |
| SPN |
Erythromycin |
B |
73 |
19 |
23 |
| Cefotaxime |
C |
0 |
16 |
4 |
|
| Enterococcus spp |
Vancomycin |
D |
4 |
10 |
0 |
| ECO |
Ceftazidime |
E |
9 |
1* |
5 |
| Cefotaxime |
F |
18 |
1* |
1 |
|
| Ceftriaxone |
G |
21 |
1* |
1 |
|
| Ciprofloxacin/Ofloxacin |
H |
56 |
3 |
26 |
|
| PAE |
Ceftazidime |
I |
17 |
9 |
27 |
| Ciprofloxacin/Ofloxacin |
J |
27 |
28 |
31 |
|
| KPN |
Ceftazidime |
K |
9 |
4* |
14 |
| Cefotaxime |
L |
17 |
4* |
13 |
|
| Ceftriaxone |
M |
20 |
4* |
13 |
|
| Ciprofloxacin |
N |
18 |
12**[27] |
18 |
|
| Salmonella spp |
Amoxicillin-clavulanate |
O |
10 |
4 |
7 |
| Ceftriaxone |
P |
5 |
1 |
0 |
|
| Ciprofloxacin |
Q |
0 |
0.4 |
10 |
|
| TMP/SMX*** |
R |
0 |
3 |
0 |
|
| Gentamicin |
S |
10 |
2 |
0 |
|
| Shigella spp |
Amoxicillin-clavulanate |
T |
35 |
2 |
20 |
| Ceftriaxone |
U |
6 |
0 |
0 |
|
| Ciprofloxacin |
V |
6 |
0 |
0 |
|
| TMP/SMX |
W |
0 |
53 |
0 |
|
| Gentamicin |
X |
18 |
0.2 |
0 |
|
| Average |
17 |
7 |
9 |
||
|
* The original U.S. NNIS reported resistance rates to either one of the Cef3 drugs, i.e. ceftazidime, cefotaxime or ceftriaxone. We assume the same rates for each drug. ** Based on surveillance of ICU patients *** TMP/SMX = Trimethoprim/Sulfamethoxazole | |||||
Zhang et al. Globalization and Health 2006 2:6 doi:10.1186/1744-8603-2-6 |
|||||